FDA
-
-
-
-
-
-
-
AveXis Announces First Patient Dosed in Phase 3 Trial of AVXS-101 in Pre-Symptomatic SMA Types 1, 2 and 3
-
-
-
-
-
-
-
AveXis (AVXS) Was a Buyout Target Before It's IPO and Had Three Other Companies Interested Before Mega Novartis Deal
-
-
-
-
-
-
-
AveXis Gene Therapy Awarded SAKIGAKE Designation for Spinal Muscular Atrophy Type 1
-
-
-
-
-
-
-
AveXis (AVXS) to Initiate Screening for Remaining Patients in AVXS-101 Trial for SMA Type 1 Following Review of Prelim. Data from First Three Patients
-
-
-
-
-
-
-
AveXis Announces Alignment with FDA on Next Steps Toward a BLA Submission for AVXS-101 in SMA Type 1
-
-
-
-
-
-
-
AveXis (AVXS): Raising PT On Strive Green Light - UBS
-
-
-
-
-
-
-
AveXis Reports Second Quarter 2017 Financial and Operating Results
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

